Alnylam Pharmaceuticals Inc (ALNY)vsMacroGenics Inc (MGNX)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
MGNX
MacroGenics Inc
$3.91
-8.00%
HEALTHCARE · Cap: $246.63M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 2629% more annual revenue ($4.29B vs $157.08M). ALNY leads profitability with a 12.6% profit margin vs -44.8%. MGNX appears more attractively valued with a PEG of 0.01. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
MGNX
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Intrinsic value data unavailable for MGNX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Growing faster than its price suggests
Revenue surging 57.5% year-over-year
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Trading at 11.8x book value
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MGNX
The strongest argument for MGNX centers on PEG Ratio, Revenue Growth. Revenue growth of 57.5% demonstrates continued momentum. PEG of 0.01 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : MGNX
The primary concerns for MGNX are Price/Book, Market Cap, Debt/Equity. Debt-to-equity of 1.72 is elevated, increasing financial risk.
Key Dynamics to Monitor
ALNY profiles as a growth stock while MGNX is a hypergrowth play — different risk/reward profiles.
MGNX carries more volatility with a beta of 1.08 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 42/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
MacroGenics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?